Amgen Plans Seven ESA Risk Studies After Latest Safety Update To Labeling
Executive Summary
Amgen is expanding its pharmacovigilance program for Aranesp and Epogen with seven new clinical trials to study risks associated with using erythropoiesis-stimulating agents to treat anemia in patients with cancer
You may also be interested in...
FDA Panel Votes To Limit ESA Cancer Use To Metastatic Patients
Following the recommendations of its Oncologic Drugs Advisory Committee, FDA's next step in ensuring the safe use of erythropoiesis-stimulating agents will be to determine how best to narrow the approved indication for anemia treatment in the cancer setting
FDA Panel Votes To Limit ESA Cancer Use To Metastatic Patients
Following the recommendations of its Oncologic Drugs Advisory Committee, FDA's next step in ensuring the safe use of erythropoiesis-stimulating agents will be to determine how best to narrow the approved indication for anemia treatment in the cancer setting
Amgen Ties Increased Transfusions To ESA Scrutiny in NCD Review Request
Amgen has released an internally generated analysis of data that draws a causal link between an increase in blood transfusions and the heightened scrutiny erythropoiesis-stimulating agents have received this year